The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1228

First 1228 Last

Share
Profile

Follow
Boffin99

2,927 Posts.

2923

30/04/24

14:49

Post #: 73585628
Share

Originally posted by ThePig: ↑

Sure. No problem.

Investors base their investment decision based on the information provided to them by companies. I have purchased oppies recently based on what was released to the market. Would I have invested had I been in possession of the information that the patient passed away? No I would not. Definitely not in the short term. I would want to know further details before I decide to buy or sell.

The fact that the Company 'hid' the information in the Quarterly deprived me of my right to be in possession of all relevant information.

Section 674 Corporations Act relates to Continuous Disclosure. It states; "(b) the entity has information that those provisions require the entity to notify to the market operator; and (c) the information is not generally available; and (d) a reasonable person would expect the information, if it were generally available, to have a material effect on the price or value of ED securities of the entity; the entity must notify the market operator of that information in accordance with those provisions."

Section 1042D relates to 'material affect' and states: "For the purposes of this Division, a reasonable person would be taken to expect information to have a material effect on the price or value of particular financial products if (and only if) the information would, or would be likely to, influence persons who commonly acquire financial products in deciding whether or not to acquire or dispose of the first - mentioned financial products."

Further, as I posted in the Quarterly thread there appears to be a discrepancy in the information provided to the market. So in my opinion based on what I have read in the EGM announcement compared to what is produced in today's Quarterly there may be a breach of Section 1041H Corporations Act which relates to misleading or deceptive conduct.

All based on my thoughts and opinions.

Expand

long story short they have not reached a trial end point so they don’t report on individual cases. The fact they gave an update in the quarterly is above and beyond what other biotechs would have done.

don’t see an issue here, Monepantel is not a cure it’s a treatment. The test is only whether it prolongs survival longer than current standard of care around 6-9 months.

i am interested to see who steps into the ring as CEO in coming months.

PAA Price at posting: 22.5¢ Sentiment: Buy Disclosure: Held
19 Upvote

2 Great analysis

Reply

Top Stories

ACW

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump is President Again: What Does This Mean for Crypto?

NHF

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

There are more pages in this discussion • 197 more messages in this thread...

First 1228 Last

Add NUZ (ASX) to my watchlist

(20min delay)
Last 18.5¢		Change -0.015(7.50%)		Mkt cap ! $90.96M

Open	High	Low	Value	Volume
20.0¢	20.0¢	18.5¢	$115.7K	598.1K

Buyers (Bids)

No.	Vol.	Price($)
9	593392	18.5¢

Sellers (Offers)

Price($)	Vol.	No.
19.0¢	4355	1

View Market Depth

No.	Vol.	Price($)
9	593392	0.185
8	337474	0.180
5	145797	0.175
4	130250	0.170
1	60000	0.165

Price($)	Vol.	No.
0.190	4355	1
0.200	77907	4
0.205	109808	2
0.210	147252	4
0.215	100000	1

Last trade - 16.10pm 12/11/2024 (20 minute delay)

NUZ (ASX) Chart

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1228

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump is President Again: What Does This Mean for Crypto?

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1228

Top Stories

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump is President Again: What Does This Mean for Crypto?

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News